No PRAME encore for Immatics
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
The company dribbles out more data on IMA203, and the numbers head in the right direction.
PRAME has become a hot target for Immatics, which is now clinically progressing two different modalities against this antigen.